AbbVie’s Diversification Bet Gradually Shows Results, While Pfizer Seeks a Second Takeoff Through Its GLP-1 and Oncology Pipelines Sep 5, 2026 Life Science
Pfizer Trades Below 10x P/E, But Does That Signal a Value Trap or a Long-Term Opportunity? Sep 4, 2026 Life Science
Eli Lilly Swallows Merida, Expanding Pipeline with Another Strategic Acquisition Sep 3, 2026 Life Science
Gene-Editing Pioneer CRISPR Therapeutics Worth a Bet Before Year-End? Two Catalysts Await Release Sep 3, 2026 Life Science
GLP-1 Concept Stock Amylyx Soars 247% Year-to-Date: How Much Room Remains for Upside? Sep 2, 2026 Life Science
Ark Invest Goes Against the Grain: Wood Bets on Nvidia and the Gene-Editing Arena Sep 1, 2026 Life Science
Eli Lilly Is on an M&A Spree—Will the $2.88 Billion Merida Deal Be Enough to Diversify? Aug 31, 2026 Life Science
Rasonque’s Lightning Approval Validates Druckenmiller’s Bet on Revolution Medicines Aug 28, 2026 Life Science
Clinical-Stage Biotechnology Company Biohaven Sees Dual Positive Developments During the Week Aug 28, 2026 Life Science
Billionaire Loads Up on Revolution Medicines, the Upside Could Be More Than 7% Aug 26, 2026 Life Science
Beyond Eli Lilly and Novo Nordisk: Overlooked Opportunities in the GLP-1 Race Aug 25, 2026 Life Science
